

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3964577

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	CHANGE OF NAME

**CONVEYING PARTY DATA**

Name	Execution Date
NOVOZYMES BIOPHARMA DK A/S	01/19/2016

**RECEIVING PARTY DATA**

<b>Name:</b>	ALBUMEDIX A/S
<b>Street Address:</b>	LOTTENBORGVEJ 26
<b>City:</b>	LYNGBY
<b>State/Country:</b>	DENMARK
<b>Postal Code:</b>	2800 KGS.

**PROPERTY NUMBERS Total: 16**

Property Type	Number
Application Number:	13504326
Application Number:	14262244
Application Number:	14863597
Application Number:	14863628
Application Number:	14863655
Application Number:	14863685
Application Number:	14863719
Application Number:	14863752
Application Number:	14863780
Application Number:	14863836
Application Number:	14863868
Application Number:	13640235
Application Number:	13463944
Application Number:	14322547
Application Number:	14385631
Application Number:	14685112

**CORRESPONDENCE DATA**

**Fax Number:** (949)760-9502

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**PATENT**

**Phone:** 949-760-0404  
**Email:** efiling@knobbe.com  
**Correspondent Name:** KNOBBE MARTENS OLSON & BEAR LLP  
**Address Line 1:** 2040 MAIN STREET  
**Address Line 2:** 14TH FLOOR  
**Address Line 4:** IRVINE, CALIFORNIA 92614

<b>ATTORNEY DOCKET NUMBER:</b>	ALBUM.000GEN
--------------------------------	--------------

<b>NAME OF SUBMITTER:</b>	ERIC FURMAN
---------------------------	-------------

<b>SIGNATURE:</b>	/Eric Furman/
-------------------	---------------

<b>DATE SIGNED:</b>	07/15/2016
---------------------	------------

**Total Attachments: 6**

source=ALBUM-000GEN\_Change\_of\_Name#page1.tif  
source=ALBUM-000GEN\_Change\_of\_Name#page2.tif  
source=ALBUM-000GEN\_Change\_of\_Name#page3.tif  
source=ALBUM-000GEN\_Change\_of\_Name#page4.tif  
source=ALBUM-000GEN\_Change\_of\_Name#page5.tif  
source=ALBUM-000GEN\_Change\_of\_Name#page6.tif



Date: 07.04.2016

**NOVOZYMES BIOPHARMA DK A/S**

<b>CVR number</b>	29603537
<b>Address</b>	Lottenborgvej 26
<b>Postal code and city</b>	2800 Kgs. Lyngby
<b>Start date</b>	29.05.2006
<b>Company type</b>	Aktieselskab
<b>Advertising protection</b>	No
<b>Status</b>	Normal

**Expanded business information**

<b>Telephone</b>	44460343
<b>Email</b>	ivad@novozymes.com
<b>Municipality</b>	Lyngby-Taarbæk
<b>Sector code</b>	464610 Engroshandel med medicinalvarer og sygeplejeartikler
<b>Objects</b>	Selskabets formål er drift af og investering i forskning, udvikling, produktion og handel med biologiske løsninger, herunder bioteknologiske produkter og processer samt at drive virksomhed, der efter bestyrelsens nærmere bestemmelse står i forbindelse hermed. Selskabet tilstræber at drive sin virksomhed på bæredygtig og ansvarlig vis, herunder i økonomisk, miljømæssig og social henseende.
<b>Secondary names</b>	Albumedix A/S NOVOZYMES ADENIUM BIOTECH A/S NOVOZYMES BIOPOLYMER A/S
<b>Registered for VAT</b>	Look it up at <a href="http://skat.dk">skat.dk</a>
<b>Financial year</b>	From 01.01 to 31.12

Latest articles of association	15.01.2016
Registered capital	612.000,00 DKK
First accounting period	29.05.2006 - 31.12.2006

Erhvervsstyrelsen, Langelinie Allé 17, 2100 København Ø

The information in this document is from The Central Business Register (CVR). The data may not be used in any way which suggests that the Danish Business Authority endorses, supports, recommends or markets the user of the data, or the services or products of the user of the data. The Danish Business Authority is not liable for the content and origin of the data, nor is it liable for any errors and omissions in the data, including for any loss or damage caused by its use.

**Attestation for Translated Material**

Title of Translated Document: Erhvervsstyrelsen/NOVOZYMES BIOPHARMA DK A/S [Danish Business Authority Business Information Document for Novozymes Biopharma DK A/S]

Language(s): Danish

I, Daniel K. Yarbrough, have prepared the attached translation. To the best of my knowledge, I declare that the translation of the document listed above is a true, accurate and a complete translation of the original text.

  
Signature

April 13, 2016

Date

23108408  
041216

Business Authority

Date: 07.04.2016

NOVOZYMES BIOPHARMA DK A/S

CVR number	29603537
Address	Lottenborgvej 26
Postal code and city	2800 Kgs. Lyngby
Start date	29.05.2006
Company type	Aktieselskab
Advertising protection	No
Status	Normal

Expanded business information

Telephone	44460343
Email	ivad@novozymes.com
Municipality	LyngbyTaaarbæk
Sector code	464610 Wholesale of pharmaceuticals and medical supplies
Objects	The company's purpose is the operation of and investment in research, development, production and trade in biological solutions, including biotechnology products and processes, and to operate according to the Board provision related thereto. The company strives to operate in a sustainable and responsible way, including in economic, environmental, and social terms.

Secondary names

Albumedix A/S  
NOVOZYMES ADENIUM BIOTECH A/S  
NOVOZYMES BIOPOLYMER A/S

Registered for VAT	Look it up at skat.dk
Financial year	From 01.01 to 31.12
Latest articles of association	15.01.2016
Registered capital	612.000,00 DKK
First accounting period	29.05.2006 - 31.12.2006

23108140  
041216

## **Novozymes separates its biopharma activities to form independent company**

**The new stand-alone company Albumedix will continue to develop albumin-based products and technologies for the pharmaceutical industry.**

19. January 2016

### **CORPORATE NEWS**

Today, Novozymes announced it has separated its biopharma activities into an independent company called Albumedix. The new company will be fully owned by Novozymes.

“Over the past nine years, our work in albumin has resulted in a series of new discoveries and technologies, which have led to agreements with major pharmaceutical and biotech companies,” says Thomas Videbæk, Executive Vice President for Business Development at Novozymes. “The business is in good shape with great prospects to make a real difference for patients all over the world. We believe it is now ready to be developed further outside Novozymes, where it will have the best possible growth conditions.”

### **Albumedix to accelerate Veltis® for half-life extension**

Albumedix will continue to develop its market leading position within recombinant albumin-based products and technologies. Albumin is a naturally occurring protein that can be found in human blood.

Named Recombumin®, Albumedix's recombinant albumins are used in the pharmaceutical industry to stabilize drugs and vaccines. For example, since 2006, Merck has used Albumedix's solutions to produce two vaccines used to treat millions of children worldwide against measles, mumps, rubella and chicken pox.

Albumin can also be used to extend the half-life of pharmaceuticals to prolong the drugs' effect and Albumedix offers a first and second generation version of this drug delivery technology under the name Veltis. In 2014, Veltis got its commercial breakthrough when GlaxoSmithKline launched a diabetes drug that utilizes the technology, allowing patients to dose weekly instead of daily. Today, Albumedix has a growing pipeline of partner-driven drug candidates evaluating Veltis.

In addition to providing albumin-based solutions to the pharmaceutical industry, Albumedix will initiate the exploration of early stage clinical drug development based on its Veltis technology and relevant drug candidates.

### **Experienced management team and board**

Albumedix will be led by CEO Peter Rosholm, who previously headed Novozymes' Biopharma business. The leadership team will report to an independent board consisting of three directors from the pharmaceutical industry and two representatives from Novozymes.

The Chairman of the Board, Don deBethizy, brings more than 15 years of experience in managing and financing life science related technologies, and has played a key role in building and advising several life science companies.

“I see a promising future for Albumedix, and together with Don deBethizy and the rest of the team I look forward to expanding our role in the pharmaceutical industry. With our heritage, expertise in albumin, and skilled employees, we have a strong foundation for developing superior biotherapeutics for patients,” says Peter Rosholm.

Albumedix will be headquartered in Lyngby, Denmark, with R&D and production facilities in Nottingham, UK. The company will employ approximately 100 people.

Novozymes retains full ownership of Albumedix and the newly created company's financial results will continue to be consolidated into Novozymes' reporting. The formation of Albumedix is not expected to impact Novozymes' financial results for 2016.

#### Albumedix CEO and Chairman of the Board

##### Peter Rosholm, CEO

Peter Rosholm has extensive international experience in business management with several expatriations to Asia and Europe. He joined Novo Nordisk's enzyme division in 1990 and has since then held a number of managerial positions within marketing and sales, before Peter Rosholm in 2006 was appointed Vice President of Novozymes' Biopharma division, now Albumedix. Peter Rosholm holds a M.Sc. and an EMBA.

Besides Peter Rosholm, Albumedix's management team will consist of Svend Erik Licht, Chief Commercial Officer, Klavs Kirk, Chief Operations Officer and Darrell Sleep, Chief Scientific Officer. All three have worked at Novozymes a number of years.

##### Don deBethizy, Chairman

Dr. Don deBethizy has many years of experience from R&D intensive industries, including over 15 years in executive positions in the biopharmaceutical industry. In those positions, Dr. deBethizy has managed large private as well as public biotech financing. He currently serves on a number of international biotech boards. Don deBethizy holds M.Sc. and Ph.D. degrees in toxicology from Utah State University.

#### About Albumedix:

**Albumedix helps biopharmaceutical companies improve patient outcomes with a range of albumin-based products and technologies that facilitate the development of superior biotherapeutics.**

Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Our products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide. With over 25 years' experience in the biopharmaceutical industry, we have the scientific, technical and regulatory expertise needed to support companies in moving faster to market with superior biotherapeutics. We also use this expertise to strengthen our own drug pipeline. Albumedix is a global company and fully owned subsidiary of Novozymes.